NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis
27. März 2023 09:28 ET
|
Translational Research in Oncology
EDMONTON, Alberta, March 27, 2023 (GLOBE NEWSWIRE) -- Translational Research In Oncology (TRIO) today announced positive topline results from NATALEE (TRIO033), a Novartis sponsored Phase III trial...
TRIO obtiene la certificación de Great Place to Work® en Uruguay
11. April 2022 09:30 ET
|
Translational Research in Oncology
-El 100% de los empleados considera que TRIO Uruguay es un gran lugar para trabajar- MONTEVIDEO, Uruguay, April 11, 2022 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), una...
TRIO recebe certificação Great Place to Work® no Uruguai
11. April 2022 09:30 ET
|
Translational Research in Oncology
-100% dos funcionários consideram o TRIO Uruguai um ótimo lugar para trabalhar- MONTEVIDÉU, Uruguai, April 11, 2022 (GLOBE NEWSWIRE) -- A Translational Research in Oncology (TRIO), uma...
TRIO Obtains the Great Place to Work® Certification in Uruguay
11. April 2022 09:30 ET
|
Translational Research in Oncology
-100% of employees consider TRIO Uruguay a great place to work- MONTEVIDEO, Uruguay, April 11, 2022 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global oncology clinical...
Trio Named To Canada’s Top Employer List For Second Straight Year
06. April 2022 11:41 ET
|
Translational Research in Oncology
- Third Time Named to Alberta’s Top Employer List - EDMONTON, April 06, 2022 (GLOBE NEWSWIRE) -- Translational Research In Oncology (TRIO), a global academic clinical research organization, is...
TRIO Enrols First Patient in Global Phase 3 Giredestrant Early Breast Cancer Trial
31. August 2021 09:00 ET
|
Translational Research in Oncology
EDMONTON, Alberta, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of first patient in the...
TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule
06. Juli 2021 07:00 ET
|
Translational Research in Oncology
EDMONTON, Alberta, July 06, 2021 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA...
Translational Research in Oncology (TRIO) Appoints Board Member
20. Mai 2021 09:00 ET
|
Translational Research in Oncology
EDMONTON, Alberta, May 20, 2021 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced the appointment of Prof. Seock-Ah Im...
TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial
21. April 2021 08:00 ET
|
Translational Research in Oncology
EDMONTON, Alberta, April 21, 2021 (GLOBE NEWSWIRE) -- Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with...
Translational Research in Oncology (TRIO) Named Top Alberta Employer for Second Year
26. Januar 2021 14:25 ET
|
Translational Research in Oncology
EDMONTON, Alberta, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, is pleased to be recognized as one of Alberta’s Top...